AbbVie is set to present new data from its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3, 2025. The presentations will cover investigational antibody-drug conjugates (ADCs) and highlight advancements in treatments for difficult-to-treat solid tumors and blood cancers.
Dr. Roopal Thakkar, AbbVie's executive vice president of research and development and chief scientific officer, stated, "The data we're presenting at this year's ASCO reflect the breadth and depth of our oncology pipeline and our unwavering commitment to research that could transform outcomes for patients facing cancer."
Key oral presentations include telisotuzumab adizutecan (ABBV-400, Temab-A), ABBV-706, and pivekimab sunirine (PVEK). Dr. Ross Camidge from the University of Colorado Cancer Center noted that "the anti-tumor activity of Temab-A in patients with pre-treated, advanced EGFR-mutated non-squamous NSCLC is encouraging."
Temab-A showed a 63% objective response rate in a Phase 1 study involving patients with advanced non-small cell lung cancer. Further studies are underway in combination therapies for various cancers.
ABBV-706 was tested on patients with high-grade neuroendocrine neoplasms, showing a 31.3% objective response rate. Pivekimab sunirine demonstrated clinical benefits in blastic plasmacytoid dendritic cell neoplasm with a composite complete response rate of 70% among untreated patients.
Dr. Daejin Abidoye, AbbVie's vice president for solid tumors, emphasized the company's commitment to expanding its ADC portfolio: "These results highlight the potential of our investigational medicines to offer a meaningful clinical benefit in multiple difficult-to-treat cancers."
AbbVie continues to explore innovative cancer therapies through various clinical trials worldwide.
Further details about AbbVie's clinical trials can be found on their website or through clinicaltrials.gov.